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Objectives: Price erosion is considered the key success criterion of generic 
drug policies. For chronic drug therapy, however, persistence with the original 
drug substance is equally important. Low persistence may result in poor health 
outcomes, lead to increased health care costs. Our objective was to estimate the 
impact of switching drug therapy on health and economic outcomes as a conse-
quence of the Hungarian drug policy in hypertension. MethOds: We retrieved 
4-year medical records of hypertensive patients, who had at least 10 prescriptions 
of original losartan or losartan HCT in the 12 months prior to patent expiry. We 
allocated patients to 3 groups based on switching history in the 12 months after 
patent expiry. Group 1 patients were switched to another patented antihyperten-
sive product without risk for generic substitution (n= 953). Group 2 patients were 
switched to generic losartan or losartan HCT, but did not change the generic brand 
in 12 months (n= 630). Group 3 patients were switched at least twice among differ-
ent generic brands in 12 months (n= 1144). We calculated the incidence of major 
cardiovascular events (MACE) and overall health care cost (289.42 HUF/EUR 2012 
average exchange rate) in each group. Results: Total 3-year health care costs were 
€ 9,728, € 6,594, € 8,227, the incidence of MACEs was 13.3%, 9.8%, 12.3% in Group 1, 2 
and 3 respectively. cOnclusiOns: In chronic diseases switching to generic drugs 
reduces health care costs. However, frequent switching among generic brands may 
result in negative health outcomes and increased health care costs. Suboptimal 
implementation of generic drug policies in chronic diseases may compromise 
expected benefits (i.e. same health gain at lower costs). Potential confounding fac-
tors may limit the generalizability of our conclusions.
PCV148
Assessment of GeneriC DruG PoliCy imPlementAtion by meAsurinG 
PersistenCe with AntihyPertensiVe DruG therAPies After PAtent 
exPiry
Abonyi-Tóth Z.1, Kalo Z.2, Ágh T.3, Inotai A.3, Katona L.4, Rokszin G.1, Jozwiak-Hagymásy J.3
1RxTarget, Szolnok, Hungary, 2Eötvös Loránd University, Budapest, Hungary, 3Syreon Research 
Institute, Budapest, Hungary, 4Semmelweis University, Budapest, Hungary
Objectives: There are two important success criteria of generic drug policies in 
chronic diseases after patent expiry: price erosion and persistence. Our objective 
was to assess the implementation of generic drug policies on these criteria between 
2007-2011 in Hungary by comparing the continuation of angiotensin receptor block-
ers after patent expiry of original therapies. MethOds: In Hungary the first generic 
losartan was launched in 2007; losartan HCT in 2009; valsartan/valsartan HCT in 
2011. From the National Health Insurance Fund database, we selected prescription 
records of hypertensive patients with at least 10 prescriptions of original losar-
tan (Group 1; n= 2637), losartan HCT (Group 2; n= 7598) and valsartan/valsartan 
HCT (Group 3; n= 38098) in the last 12 months prior to patent expiry. We compared 
antihypertensive therapies in 12 months after the reimbursement of first generic 
drug in each group. Antihypertensives were categorized into preferred (continued 
antihypertensive therapy with same active ingredient generic drugs), and non-pre-
ferred (continuation on original drug therapy; switching to other patented drug(s) 
without risk for generic substitution; switching to generic drugs with other active 
ingredient(s); discontinuation of reimbursed antihypertensive drug therapies) policy 
outcomes. Results: After patent expiry 76.2% and 68.9% of Group 1&2 patients 
continued the original losartan or losartan HCT therapy for 12 months, and only 
3.9% and 8.5% were switched to generic losartan/losartan HCT. In Group 3, 33.6% 
of patients were switched to generic valsartan/valsartan HCT, 42.8% received other 
generic drugs or drug combinations, whilst 14.5% were switched to other patented 
products. cOnclusiOns: Despite significant changes in the generic drug policies 
in Hungary in 2007, 2009 and 2011 not more than one-third of hypertensive patients 
changed to generic drugs during 12 months after first generic entry. These findings 
indicate suboptimal generic drug policy in a chronic disease with significant public 
health implications.
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Objectives: To review the consumption pattern of ambulatory high expenditure 
therapeutic groups in Portugal following prescribing guidelines set forth by the 
Memorandum of Understanding; to perform a cross-country comparison of utili-
zation patterns focusing on quality prescribing indicators identified by the EURO-
MED-STAT and/or major international prescribing guidelines; and to perform a 
cost-saving scenario analysis if more rational European prescribing patterns were 
undertaken in Portugal. MethOds: Cross-national drug utilization study with 
data from seven European countries: Portugal, Denmark, England, Finland, The 
Netherlands, Norway and Sweden. Data from Portugal retrieved from hmR Pharmacy 
Sales Information System, a nationwide database with representative pharmacy 
dispensing data. Data from other countries was selected from published literature 
and/or public databases. Cost-saving analysis with assumptions: average annual 
cost per defined daily dose (DDD) from Portugal and simulations to measure the 
impact on total expenditure of international utilization patterns (DDD proportion) 
versus Portuguese pattern. Results: Portugal has the highest consumption of 
oral antidiabetic combinations (19.3% in 2010), of Antagonists Reception Blockers 
(ARBs) (31% in 2009), and of rosuvastatin (22.2% in 2011). A total of 236 Million euro 
annual cost-savings was estimated in scenarios of more rational prescribing: 100 
Million euro (58% decrease in costs of antidiabetic agents in 2010) when simulating 
the Dutch oral antidiabetic prescribing pattern; 106 Million euro when simulating 
the Danish antihypertensive prescribing pattern (20% decrease in antihypertensive 
costs in 2009); and 26 Million euro when simulating the UK statin prescribing pat-
tern (13% decrease in statin costs in 2011). cOnclusiOns: It is crucial to optimize 
prescribing patterns in Portugal, in order to achieve a more rational use of medi-
cines and a sustained control of pharmaceutical expenditure. Besides prescribing 
Objectives: To review the literature about adherence to warfarin treatment 
in Brazil. MethOds: A systematic review of the literature and a wide search 
in LILACS (Literatura Latino Americana e do Caribe em Ciências da Saúde) and 
MEDLINE (Medlars On Line) electronic databases were conducted to identify 
studies with the key words: “warfarin” and “Brazil”. The combination of terms 
was used as reference for the analysis. Search was restricted to randomized con-
trolled trials (RCT), systematic reviews, meta-analysis and prospective clinical 
trials (PCT). Results: A total of 77 studies were identified, from which only 22 
met inclusion criteria: 1 meta-analysis, 5 RCTs, 8 systematic reviews and 8 PCTs. 
Only 1 study described adherence to treatment. From a total of 229 randomized 
patients, 119 received warfarin. Adherence to treatment was observed in 42% 
(p= 0.001) of patients using warfarin considering an average of 57+-18 months 
of follow-up, INR < 2 in 37.54 % and INR > 2 in 11.18 %. Multivariate analysis 
estimated that every 1% of INR < 2, the risk of a thromboembolic event increases 
8.4%. cOnclusiOns: The systematic review of the literature showed lack of 
data regarding Brazilian patients under warfarin treatment. The only available 
study did not define adherence and it did not investigate the underlying causes 
of non-adherence. Thus, it is recommended the conduction of further studies 
in order to provide better understanding of anticoagulant therapies compliance 
in Brazilian patients.
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Objectives: Potentially avoidable hospitalizations (PAH) are increasing in Spain 
and account for more than 3% of all the discharges. One of the hypothesis to 
explain PAH lies on the suboptimal management of chronic disease at ambulatory 
level of care. In this study we aim at explaining the association between compli-
ance with preventive recommendations in primary care and observed rate of 
PAH. MethOds: Compliance with evidence-based preventive recommendations 
regarding diabetes mellitus (DM), chronic heart failure (CHF) and chronic obstruc-
tive pulmonary disease (COPD) was calculated for the 1,350 general practition-
ers of the Basque Health Service and compared with the annual (2011) observed 
rate of PAH between their patients’ panel (mean panel≈1,500 adults; population 
covered= 1,942,873). PAH was defined by a restrictive set of ICD-9 criteria follow-
ing recommendations of the Spanish group of studies on Variability in Medical 
Practice. Multilevel poisson regression was used and age, sex, status socioeco-
nomic (SSE) and hospital of reference were entered as covariates. Results: After 
adjusting by all the covariates, higher compliance of recommendations such as 
periodical spirometry or assessment of the correct use of bronchodilator inhalers 
shows association with lower rates of PAH by COPD (p< 0.05). Periodical foot care, 
oftalmological exam or assessment of the cardiovascular risk is non-significantly 
(0.15≥ p≥ 0.05) but consistently associated to lower rates of PAH by DM. No link was 
observed between compliance or recommendations for CHF and PAH due to this 
cause. The independent effect of the SSE was strong in all the diseases (p< 0.001) 
(higher rates as privation increases). Variations regarding the hospital of refer-
ence were also observed. cOnclusiOns: Adequate compliance of evidence-based 
recommendations limits, modestly but consistently, the incidence of PAH due to 
DM or COPD. The SSE and the hospital of reference explain part of the observed 
variability in hospitalization by chronic disease.
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Objectives: We investigated opportunities to cost-effectively improve health out-
comes for patients eligible for ICD, sICD and CRT-D devices. This area was chosen 
because of the high cost of these devices and the significant amount of uncertainty 
on how to use them in a cost effective way. Also, we aimed to explore value-added 
services to patients and physicians, and the area appeared to have potential for 
this. MethOds: We conducted a value chain analysis. The first step was to clarify 
the care pathway and identify places where outcome or efficiency were poor; the 
second step was to prioritise the associated problems based on their importance 
(health/cost impact) and the feasibility of addressing the root causes in the short to 
medium term; the third step was to propose ways to address the priority problems 
and add value in the care pathway. To do this, we conducted secondary research, and 
primary research mainly focused on the UK (20 in-depth discussions with cardiolo-
gists, patients and manufacturers). Results: A core issue was the lack of good evi-
dence-based criteria to identify which patients would benefit most from the various 
devices. Referral to device implantation and funding were seen as below the levels 
expected given current clinical and HTA guidelines; the gap might even increase 
given the expectation that future guidelines may call for higher implantation rates. 
The proposed solutions focused on increasing awareness of the guidelines for more 
effective referral to specialist centres, supporting more flexibility in local funding, 
and taking advantage of the rich, continuous data that the devices themselves could 
provide with a view to eventually improve eligibility criteria. cOnclusiOns: It 
is increasingly difficult to achieve health gains through new therapies. Therefore, 
focusing on improving referral and delivery pathways of current therapies may be 
quite effective at increasing health gains and/or efficiency.
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